Source Prompt Coverage Map
The original Japanese prompt remains the methodological authority. The skill reorganizes it into progressive research instructions, a source-linked schema, deterministic calculations, audit statuses, and tests.
| Original prompt area | Skill implementation |
|---|---|
| Undervalued growth rather than low P/E | SKILL.md overview; methodology objective; minimum constant-multiple upside gate |
| NYSE/Nasdaq/NYSE American and USD 500M–20B focus | scope/configuration and screening funnel |
| Exclusions and liquidity | corporate-action preflight, flags, liquidity gates, hard-exclusion log |
| SEC/IR source priority | evidence map, source ledger, research checklist, data-quality weights |
| Consensus date/period/type/analyst count | separate current/year-2/year-3 valuation records |
| Price timestamp/session and post-event consistency | common price basis, latest-event timestamp, stale-data gate |
| Revenue, EPS, FCF-per-share growth | historical CAGRs and forward per-share periods |
| ROIC, margins, leverage | normalized financials and score components |
| Standard FCF = OCF − capex | non-negative capex convention and three TTM reconstruction methods |
| Company-adjusted FCF disclosure | separate supplemental field and definition; never substitutes for standard FCF |
| GAAP vs non-GAAP | per-period metric basis and arithmetic GAAP reconciliation |
| SBC, dilution, and actual buybacks | SBC/FCF metrics, diluted-share history, explicit penalties |
| Three-to-five genuine peers | sourced peer rows, basis/period validation, peer-median scenario |
| Strict cyclical review | sourced normalization object and fail-closed gate |
| Latest earnings and growth-state classification | latest-earnings object and full report section |
| Sector-specific KPI rules | sector profile; commercial-biopharma LOE and payments cash/take-rate controls |
| Earnings/accounting quality | TTM reconstruction, working-capital review, source checklist |
| Constant multiple, 20% contraction, peer median | deterministic evaluator |
| EPS/FCF forecast construction | numerator/denominator bridge, drivers, arithmetic tolerance |
| Why discounted and market may be right | qualitative contract and report section |
| Catalysts, risk, and invalidation | detailed candidate and final-three sections |
| 100-point ranking | seven preserved score components plus deterministic penalties |
| Complete output contract | full Markdown renderer and structured JSON |
| Do not guess or force recommendations | null contract, evidence gates, review status, no-qualifier result |
| Preserve incomplete work honestly | checkpoint manager and provisional partial-run status |
Version 2 Enhancements
- Corporate-action preflight runs before detailed financial research, catching completed acquisitions and inactive symbols early.
- Data-quality points require resolving evidence and arithmetic; self-attested completeness flags are ignored.
- Capex sign convention is explicit and negative normalized outflows fail closed.
- TTM OCF/capex supports four discrete quarters or FY+YTD−prior YTD without double-counting cumulative statements.
- Standard FCF and company-adjusted FCF are separate.
- Corporate cash is separated from customer/settlement and restricted funds.
- Current, year-2, and year-3 accounting bases are stored separately; mixed bases block scenarios.
- Adjusted/normalized periods require GAAP reconciliation.
screened_outis distinct from hardexcluded.- Long runs checkpoint every candidate and can resume.
- Partial coverage produces a provisional report with no final-three claims.
- Commercial-biopharma LOE and payments take-rate/cash controls are explicit.
- Full Markdown output now follows all major sections of the original prompt.
- Synthetic tests cover evidence, FCF, period basis, corporate actions, sector controls, partial runs, and packaging behavior.
Version 3 Review-Driven Controls
| Original requirement | v3 implementation |
|---|---|
| Current market valuation, rates, economy, sector cycle | Mandatory sourced market_context; placeholders/future dates rejected |
| Latest price and latest earnings | Quote/event timestamp gate; latest quarter and full year separated |
| Forward P/E constant-multiple analysis | NTM/FY1 current metric required; TTM supplemental only |
| Do not uncritically use consensus | Analyst-count/range and rankable-horizon controls; forecast bridge required |
| Compare 3–5 peers | Same-basis sourced peer gate |
| Do not mechanically reject 21–30x high growers | Broad-screen high-growth exception |
| Industry-specific leverage | Auto-dealer floorplan-adjusted leverage gate |
| Product concentration and structural risk | Derived/sourced commercial-biopharma concentration and LOE stress |
| Important numbers need source/period/retrieval date | Strict source ledger with typed supports arrays |
| Scope and candidate counts | Full listing audit plus bounded candidate-pool artifact, explicit scope, enrichment counts, and SHA-256 |
| Do not recommend when conditions are unmet | --require-final, no final-three on provisional runs, explicit no-candidate result |
Version 3.1 Execution Controls
| Original requirement | v3.5 execution implementation |
|---|---|
| Screen the major US exchanges, with emphasis on USD 500M–20B | Full listing-universe audit records requested and retrieved bounds; reduced scope is disclosed and cannot silently complete |
| Do not guess missing numbers | Missing discovery data is needs_enrichment; no placeholder zeros or scores |
| Use multiple metrics but respect industry characteristics | General-company candidate screen plus explicit sector-review routing for banks, REITs, insurers, BDCs, MLPs, cyclicals, and auto dealers |
| Do not force ten recommendations | Deep-dive set is bounded; evidence-based no_candidates is a valid final result |
| Important data must be current and sourced | Full listing source, candidate-estimate source, SEC/IR sources, artifact hashes, and timestamps are separate |
| Conditions not met means no recommendation | insufficient_data triggers more discovery; it is never relabeled as “no candidates” |
| Complete the task from the screening request | Plan-gated bulk statements automatically route to provider-prefilter or stratified estimate enrichment before selected-name primary-source underwriting |
Version 3.3 Evidence and Runtime Controls
| Original requirement | v3.5 implementation |
|---|---|
| Do not mix old and current data/processes | Runtime version, contract, schema, and fingerprint are embedded and hard-validated. |
| Do not uncritically use consensus | EPS/FCF is independently rebuilt from operating drivers; circular numerator checks fail. |
| Distinguish GAAP and adjusted forecasts | Driver-derived GAAP and after-tax adjustments separately tie to the reconciliation. |
| Standard FCF and source period integrity | TTM construction method and every component-period source are verified. |
| Do not overstate cash or EV/FCF | Corporate cash normalization and customer/restricted-fund separation feed evaluator-calculated EV. |
| Treat product concentration/LOE structurally | Biopharma aliases normalize to commercial-biopharma and require concentration/LOE/6x/8x stress. |
| Do not use peak cyclical profits | peak_profit_risk=true forces sourced normalization even with a low numeric cycle score. |
| Important numbers need sources | ROIC, EBITDA, cash, TTM periods, sector evidence, and forecasts affect quality points and caps. |
| Do not overclaim scope | Audited bounded pools produce explicitly scoped conclusions; market-wide no-candidates requires full economic coverage. |
Version 3.5 Discovery and Autonomy Controls
| Original requirement | v3.5 implementation |
|---|---|
| Screen the requested US small/mid-cap range | Immutable user_requested_scope plus separately audited executed_scope; internal single-band narrowing is rejected |
| Exclude extreme illiquidity using trading liquidity | 20+ session ADDV provenance contract; raw one-session volume is ignored |
| Use current Forward P/E and do not mix periods | Dated NTM/FY1 normalization, price/EPS reconciliation, analyst breadth, range-dispersion and continuity checks |
| Do not force the user to supervise internal steps | Exit code 2 and next-action are same-execution continuation; selected-set commitment requires every selected name to finish |